The biotechnology company has raised £13,200 through the exercise of warrants, issuing new shares at a 55% discount to the previous closing price. This large discount suggests low investor confidence and could signal financial distress.
The biotechnology company has raised £13,200 through the exercise of broker warrants, but at a 54.55% discount to the previous closing price, suggesting low market confidence.
The pharmaceutical company reports positive results from its analysis of lung tissue samples, suggesting its lead drug candidate NXP002 has potential to treat fibrotic diseases like IPF and autoimmune ILD.
The pharmaceutical company has posted its annual report and notice of the upcoming annual general meeting.
The pharmaceutical developer has announced a £168,750 placing to progress its pipeline and fund general corporate purposes. The raise represents a 17.6% dilution of existing shares, but is being conducted at a premium to the current share price.
The biotechnology firm reported a substantial annual loss and critically low cash reserves, emphasizing its focus on partnering its lead asset NXP002 for idiopathic pulmonary fibrosis treatment to secure its financial future.
The pharmaceutical company has submitted an application for Orphan Drug Designation for its lead asset NXP002, a potential treatment for Idiopathic Pulmonary Fibrosis.
The pharmaceutical company has submitted a draft application for Orphan Drug Designation of its lead asset NXP002 for the treatment of Idiopathic Pulmonary Fibrosis.
Pharmaceutical firm Nuformix sees directors boost their stake, signaling confidence in the company's future.
Biotech firm raises funds at steep discount